Rafael Santana-Davila
Fred Hutch/University of Washington Cancer Consortium · Medical College of Wisconsin
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rafael Santana-Davila as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:36 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05935774 · OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung CancerUniversity of Washington · withdrawn · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 · principal investigator
- Ph1/Ph2NCT05191797 · Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung CancerUniversity of Washington · terminated · Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma · principal investigator
- Ph1/Ph2NCT02846792 · Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung CancerUniversity of Washington · terminated · ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma · principal investigator
- Ph2NCT01671332 · Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung CancerUniversity of Wisconsin, Madison · completed · Carcinoma, Non Small Cell Lung · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Biostatistics and Data Science CoreP50CA228944 · NCI · FRED HUTCHINSON CANCER CENTER · PI Mary W Redman · fiscal years 2019 to 2026Named on NCT05191797
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026Named on NCT02846792
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:36 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.Clin Cancer Res · 2019280 citationsRCR 9.8
- 225 citationsRCR 7.1
- A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.Clin Cancer Res · 2020158 citationsRCR 6.8
- 133 citationsRCR 6.0
- 115 citationsRCR 5.4
- A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.Clin Cancer Res · 201893 citationsRCR 2.9
- 88 citationsRCR 5.2
- 64 citationsRCR 11.9
- Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.J Thorac Oncol · 202155 citationsRCR 2.2
- A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.Clin Cancer Res · 202447 citationsRCR 4.3